SearchDictionaryMobileLogin

Ben Davidson Selected Research

Carcinoma (Carcinomatosis)

04/2008Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
01/2008Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma.
09/2007Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma.
07/2007Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions.
02/2007Heparanase expression correlates with poor survival in metastatic ovarian carcinoma.
01/2007The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma.
12/2006The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
11/2006Expression of E-cadherin transcriptional regulators in ovarian carcinoma.
09/2006The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma.
07/2006Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.
03/2006The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma.
11/2005Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities.
06/2005Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma.
03/2005Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions.
01/2005HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
05/2004Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
05/2004The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma.
01/2004Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma.
01/2004The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.
10/2003Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions.
06/2003Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.
04/2003PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma.
03/2003Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?
01/2003Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma.
01/2003Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma.
01/2003EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma.
02/2002The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma.
02/2002Caveolin-1 expression in ovarian carcinoma is MDR1 independent.
01/2002Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.

Articles by Research Topic

Disease

29Carcinoma (Carcinomatosis)
04/2008 - 01/2002
10Neoplasms (Cancer)
07/2008 - 05/2002
6Mesothelioma
07/2007 - 01/2004
4Ovarian Neoplasms (Ovarian Cancer)
01/2008 - 07/2004
1Adenocarcinoma
09/2008
1Tissue Adhesions
07/2008
1Melanoma (Melanoma, Malignant)
11/2006
1Thyroid Neoplasms (Thyroid Cancer)
05/2006

Drug/Important Bio-Agent (IBA)

3kallikrein 4IBA
02/2007 - 07/2004
3Nerve Growth Factor Receptor (Nerve Growth Factor Receptor, Low Affinity)IBA
01/2007 - 06/2003
3Mitogen-Activated Protein KinasesIBA
09/2006 - 01/2003
3Laminin ReceptorsIBA
11/2005 - 01/2003
3Matrix MetalloproteinasesIBA
03/2003 - 05/2002
2heparanaseIBA
02/2007 - 01/2004
2HLA-G antigen (HLA G)IBA
07/2006 - 01/2005
2Laminin (Merosin)IBA
06/2005 - 05/2004
2Nerve Growth Factor Receptors (Neurotrophin Receptors)IBA
05/2004 - 01/2004
2Carbon MonoxideIBA
01/2004 - 01/2003
2CD147 Antigens (Basigin)IBA
01/2003 - 01/2003
1CXCR4 Receptors (CXCR4 Receptor)IBA
09/2008
1Serrate proteinsIBA
07/2008
1Leukocyte L1 Antigen Complex (Calgranulin)IBA
04/2008
1MicroRNAs (MicroRNA)IBA
01/2008
1Proteins (Proteins, Gene)IBA
11/2007
1Cyclin EIBA
09/2007
1ZincIBA
07/2007
1Inhibitor of Apoptosis ProteinsIBA
07/2007
1Phospholipases A2 (Phospholipase A2)IBA
12/2006
1Protein Isoforms (Isoforms)IBA
12/2006
1Cadherins (E-Cadherin)IBA
11/2006
1JNK Mitogen-Activated Protein KinasesIBA
11/2006
1p38 Mitogen-Activated Protein KinasesIBA
09/2006
1Transcription Factor AP-2IBA
03/2006
1Xeroderma Pigmentosum Group A ProteinIBA
06/2005
1ApolipoproteinsIBA
01/2005
1Paclitaxel (Taxol)FDA LinkGeneric
07/2004
1DNA (Deoxyribonucleic Acid)IBA
06/2004
1ChromatinIBA
06/2004
1granulin precursor proteinIBA
05/2004
1Dual-Specificity PhosphatasesIBA
05/2004
1transcription factor PEA3IBA
01/2004
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
01/2004
1Transcription Factors (Transcription Factor)IBA
04/2003
1Proto-Oncogene Proteins c-etsIBA
03/2003
1Integrin alpha6IBA
01/2003
1Metalloproteases (Metalloproteinases)IBA
02/2002
1Caveolin 1IBA
02/2002
1Interleukin-8 (Interleukin 8)IBA
01/2002
1Messenger RNA (mRNA)IBA
01/2002
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2002

Therapy/Procedure

2Drug Therapy (Chemotherapy)
01/2008 - 01/2005